Telavancin Efficacy Against Difficult-to-Treat Pathogens
Three studies evaluated the efficacy of telavancin against difficult-to-treat pathogens. Photo Credit: National Institute of Allergy and Infectious Diseases (NIAID).
Theravance announced positive data from 3 studies evaluating Vibativ (telavancin) at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Vienna, Austria.
Vibativ, a lipoglycopeptide antibiotic, is indicated for complicated skin and skin structure infections due to susceptible gram (+) bacteria; and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) due to Staphylococcus aureus.
In the first presentation, study data showed Vibativ had the highest in vitro activity compared to all antibiotics evaluated against a broad collection of difficult-to-treat S aureus clinical isolates, including methicillin-resistant (MRSA) and methicillin-susceptible (MSSA). Vibativ was active against 100% of all evaluated isolates, including those considered to be multidrug-resistant (MDR). The minimum inhibitory concentrations (MICs) for Vibativ were 8 to 16-fold lower than for vancomycin, daptomycin, and linezolid against MRSA or MDR isolates.
In the second presentation, study authors presented that Vibativ had higher in vivo potency compared to vancomycin against S aureus in neutropenic murine thigh and lung infection models. MIC measurements proved to be significant predictors of treatment efficacy against the studied infections. The favorable in vivo data further confirm the ongoing use of Vibativ for its use in HABP/VABP due to S aureus, including MRSA.
In the third presentation, the pharmacokinetic profile of Vibativ was evaluated when administered as a single, stratified, fixed weight-based dose in obese patients. The data showed higher Vibativ distribution and clearance levels in moderately to severely obese patients vs normal weight or mildly obese patients.
Vibativ is available as 750mg strength powder per single-use vial in 10-count packs.
Theravance Biopharma reports positive clinical response rates for patients in TOUR observational patient registry in several presentations at ECCMID 2017 [press release]. San Francisco, CA: Theravance Biopharma. Published April 24, 2017. Accessed May 1, 2017.